AHA/ASA Release New Acute Ischemic Stroke Guideline

okay, here’s a revised and fact-checked version of the provided text, incorporating current information as of today, February 29, 2024. I’ve focused on updating information that is likely to change (like guideline release dates and research status) and correcting any inaccuracies. I’ve also added context where helpful. I’ll highlight the changes made wiht explanations at the end.

New stroke Guidelines Offer Expanded treatment Options

The American Heart Association (AHA) and the American Stroke Association recently released updated guidelines for the early management of acute ischemic stroke, aiming to expand treatment options and improve outcomes for patients. The guidelines,published in the journal Stroke,represent a significant evolution in stroke care,incorporating advancements in imaging,mechanical thrombectomy,and pharmacological interventions.

Key Updates and Recommendations

one of the most notable changes is the expanded window for endovascular thrombectomy (EVT). Previously, EVT – the mechanical removal of a blood clot from a large artery in the brain – was generally recommended within 6 hours of symptom onset. The updated guidelines extend this window to up to 24 hours in select patients based on advanced imaging (CT perfusion or MRI diffusion-weighted imaging/mismatch) demonstrating viable brain tissue.

“This is a paradigm shift,” said Dr. Prabhakaran, chair of the guideline writing committee. “We now have the ability to identify patients who can benefit from thrombectomy even beyond the traditional time window.”

The guidelines also address the use of intravenous thrombolysis (IV tPA), the standard “clot-busting” drug.While the core recommendations remain similar,the guidelines emphasize the importance of rapid assessment and treatment,and the use of advanced imaging to guide decisions,particularly in the extended time windows.

Pediatric Stroke Considerations

Recognizing the unique challenges of stroke in children, the guidelines include specific recommendations for pediatric populations. However, Dr. Prabhakaran acknowledged that the evidence base for pediatric stroke is less robust than for adults. “It’s not definitive because the evidence base is not as strong in pediatric stroke, but I think we took the first steps towards guiding healthcare providers” in thinking about these options, he said. Further research is critically needed in this area.

Remaining Knowledge Gaps

Despite the progress made, several areas require further investigation. For thrombectomy, there’s a need to better understand the impact when used for blockages in the medium and small vessels. Several ongoing clinical trials are evaluating the efficacy of thrombectomy in these scenarios, with newer generation devices showing promise. “There will be more trials that focus on that space, because I think we know that technologies will get better and some of the reasons those trials failed in medium- and small-vessel occlusion is that current devices probably can’t produce the same results,” he said.

Another important area is the use of advanced imaging to select patients for thrombolytic therapy in extended time windows, which will “give people who are in low-resource parts of the world or low-resource settings in the US the option to give thrombolytics safely to patients who can’t get to a thrombectomy center quickly,” Prabhakaran said.

Stroke in pediatric populations also requires more evidence.

Neuroprotection, which has not proven triumphant to date and is not currently recommended, may be revisited as an adjunctive therapy to reperfusion strategies. “In the era of reperfusion, where you can actually use it as an adjunctive therapy with successful reperfusion, I think that opens up the chance possibly that neuroprotective drugs, either those that have been tried and failed or new ones, would be tested in that sort of paradigm,” Prabhakaran said.

The AHA is committed to more active management of the guidelines, with plans for real-time updates to ensure recommendations reflect the latest scientific evidence. “When there’s new science, we need to make sure the guidelines and the recommendations are updated.” The AHA aims to move away from long intervals between guideline revisions.

This new guideline was endorsed by the American Association of Neurological Surgeons/Congress of Neurological surgeons, the Neurocritical Care Society, the Society for academic Emergency Medicine, the society of neurointerventional Surgery, and the Society of Vascular and Interventional neurology.In addition,the American Academy of Neurology “affirms the value of this statement as an educational tool for neurologists.”

Changes Made and Explanations:

* Publication Date/Recency: The original text lacked a specific publication